Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guideline – Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Ann Oncol. 2023;34(1):33-47.
C. Sessa, J. Balmaña, S.L. Bober, et al, on behalf of the ESMO Guidelines Committee

  • This guideline provides recommendations for risk-reduction and screening for individuals with a hereditary breast and ovarian cancer syndrome.
  • This guideline focuses on risk-reduction and screening mainly in unaffected carriers and particularly in high-resource settings.
  • The panel encompasses an international multidisciplinary group of experts. 
  • Recommendations are based on available scientific data and the authors’ collective expert opinion.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.